Trump Rescheduling Plan Gains Congressional Momentum Amid Bipartisan Support
Lawmakers signal low likelihood of blocking cannabis rescheduling as hearings begin, clearing regulatory path for industry transformation.
Congressional hearings on cannabis rescheduling reveal diminishing opposition to the Trump administration's reform agenda, with bipartisan lawmakers indicating minimal appetite for blocking the regulatory overhaul. The House Appropriations Committee's recent funding bill included language that could theoretically prevent federal officials from implementing rescheduling, but political momentum suggests such measures face an uphill battle in the current legislative environment.
The regulatory shift from Schedule I to Schedule III represents the most transformative policy change in cannabis industry history, potentially unlocking billions in tax savings through 280E relief while legitimizing medical cannabis research and banking relationships. Multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries stand to benefit most dramatically, as the tax burden elimination could boost margins by 15-30% across the sector.
Cannabis companies have already begun pricing in rescheduling benefits, with the AdvisorShares Pure US Cannabis ETF gaining over 40% since election results confirmed Republican control. However, implementation timelines remain fluid, as the Drug Enforcement Administration must complete its review process and finalize new regulations before operators can claim 280E deductions on federal returns.
The bipartisan support signals a broader shift in cannabis policy calculus, moving beyond traditional partisan divides toward pragmatic economic considerations. State-legal cannabis markets generated over $29 billion in sales last year, creating substantial tax revenue and employment that even conservative lawmakers recognize as economically beneficial to their districts.
Investors should monitor the DEA's final rule publication and subsequent Treasury guidance on tax implementation, as these regulatory milestones will trigger the next wave of institutional investment and valuation adjustments across publicly traded cannabis operators. The regulatory clarity removes a major overhang that has suppressed cannabis valuations relative to traditional consumer goods companies with similar revenue profiles.